Latanoprost-Bimatoprost
PreclinicalSmall molecule
Latanoprost-Bimatoprost is one of 4 small molecule programs targeting Angle-Closure Glaucoma. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Angle-Closure Glaucoma
#DrugCompanyPhaseTrials
1Diamox
TevaApproved
Isopto Carpine
AAdvanz Pharma
Approved
Rho-Kinase Inhibitor
NNew York Glaucoma Research Institute
Phase 2
Latanoprost-Bimatoprost
SSingapore National Eye Centre
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Latanoprost-Bimatoprost. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SSingapore National Eye Centre